Suhendan Ekmekcioglu

Prof. Suhendan Ekmekcioglu

University of Texas, MD Anderson Cancer Center, Houston, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
SKSun-Hee Kim
Sun-Hee Kim
Jason RoszikJason Roszik
Jason Roszik
EGElizabeth A. Grimm
Elizabeth A. Grimm
Suhendan EkmekciogluSuhendan Ekmekcioglu
Suhendan Ekmekcioglu
The progression from neoplastic initiation to malignancy happens in part because of the failure of immune surveillance. Cancer cells successfully escape immune recognition and elimination and create an immune-suppressive microenvironment. A suppressive metabolic microenvironment may also contribute to ineffective T-cell function. Tumor progression is characterized by a complex network of interactions among different cell types that cooperatively exploit metabolic reprogramming. As we start to recognize that cancer cells use different metabolism processes than normal cells do, a better understanding of the functional mechanisms of the regulation and reprogramming of the metabolic landscape in cancer cells is crucial to successful immunotherapy strategies. However, the exact role of metabolism in T cells and in the tumor microenvironment is not known. One pathway that plays an important role in the regulation of immune cell reactivity is arginine metabolism, which has complex cellular functions. l-arginine and its downstream metabolites (e.g., ornithine and citrulline) could be essential to T-cell activation and thus modulate innate and adaptive immunity to further promote tumor survival and growth. Identifying metabolic targets that mediate immunosuppression and are fundamental to sustaining tumor growth is key to increasing the efficacy of immunotherapies.

1 November 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PDF file
KTKeiji Tanese
Keiji Tanese
YHYuuri Hashimoto
Yuuri Hashimoto
ZBZuzana Berkova
Zuzana Berkova
YWYuling Wang
Yuling Wang
FSFelipe Samaniego
Felipe Samaniego
EGElizabeth A. Grimm
Elizabeth A. Grimm

28 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
BWBofei Wang
Bofei Wang
PRPatrick K. Reville
Patrick K. Reville
MYMhd Yousuf Yassouf
Mhd Yousuf Yassouf
FJFatima Zahra Jelloul
Fatima Zahra Jelloul
CLChristopher Ly
Christopher Ly
HAHussein A. Abbas
Hussein A. Abbas
Interferon gamma (IFNγ) is a critical cytokine known for its diverse roles in immune regulation, inflammation, and tumor surveillance. However, while IFNγ levels were elevated in sera of most newly diagnosed acute myeloid leukemia (AML) patients, its complex interplay in AML remains insufficiently understood. We aim to characterize these complex interactions through comprehensive bulk and single-cell approaches in bone marrow of newly diagnosed AML patients. We identify monocytic AML as having a unique microenvironment characterized by IFNγ producing T and NK cells, high IFNγ signaling, and immunosuppressive features. IFNγ signaling score strongly correlates with venetoclax resistance in primary AML patient cells. Additionally, IFNγ treatment of primary AML patient cells increased venetoclax resistance. Lastly, a parsimonious 47-gene IFNγ score demonstrates robust prognostic value. In summary, our findings suggest that inhibiting IFNγ is a potential treatment strategy to overcoming venetoclax resistance and immune evasion in AML patients.

4 February 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
YFYasunari Fukuda
Yasunari Fukuda
MBMatias A. Bustos
Matias A. Bustos
SCSung-Nam Cho
Sung-Nam Cho
JRJason Roszik
Jason Roszik
SRSuyeon Ryu
Suyeon Ryu
Suhendan EkmekciogluSuhendan Ekmekcioglu
Suhendan Ekmekcioglu
Soluble forms of receptors play distinctive roles in modulating signal-transduction pathways. Soluble CD74 (sCD74) has been identified in sera of inflammatory diseases and implicated in their pathophysiology; however, few relevant data are available in the context of cancer. Here we assessed the composition and production mechanisms, as well as the clinical significance and biological properties, of sCD74 in melanoma. Serum sCD74 levels were significantly elevated in advanced melanoma patients compared with normal healthy donors, and the high ratio of sCD74 to macrophage-migration inhibitory factor (MIF) conferred significant predictive value for prolonged survival in these patients (p = 0.0035). Secretion of sCD74 was observed primarily in melanoma cell lines as well as a THP-1 line of macrophages from monocytes and primary macrophages, especially in response to interferon-γ (IFN-γ). A predominant form that showed clinical relevance was the 25-KDa sCD74, which originated from the 33-KDa isoform of CD74. The release of this sCD74 was regulated by either a disintegrin and metalloproteinase-mediated cell-surface cleavage or cysteine-protease-mediated lysosomal cleavage, depending on cell types. Both recombinant and THP-1 macrophage-released endogenous sCD74 suppressed melanoma cell growth and induced apoptosis under IFN-γ stimulatory conditions via inhibiting the MIF/CD74/AKT-survival pathway. Our findings demonstrate that the interplay between sCD74 and MIF regulates tumor progression and determines patient outcomes in advanced melanoma.

14 June 2016 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
Suhendan EkmekciogluSuhendan Ekmekcioglu
Suhendan Ekmekcioglu
MDMichael A. Davies
Michael A. Davies
KTKeiji Tanese
Keiji Tanese
Jason RoszikJason Roszik
Jason Roszik
MSMyung Shin-Sim
Myung Shin-Sim
EGElizabeth A. Grimm
Elizabeth A. Grimm
Purpose: Inflammatory marker expression in stage III melanoma tumors was evaluated for association with outcome, using two independent cohorts of stage III melanoma patients' tumor tissues. Experimental Design: Fifteen markers of interest were selected for analysis, and their expression in melanoma tissues was determined by immunohistochemistry. Proteins associating with either overall survival (OS) or recurrence-free survival (RFS) in the retrospective discovery tissue microarray (TMA; n = 158) were subsequently evaluated in an independent validation TMA (n = 114). Cox proportional hazards regression models were used to assess the association between survival parameters and covariates, the Kaplan–Meier method to estimate the distribution of survival, and the log-rank test to compare distributions. Results: Expression of CD74 on melanoma cells was unique, and in the discovery TMA, it associated with favorable patient outcome (OS: HR, 0.53; P = 0.01 and RFS: HR, 0.56; P = 0.01). The validation data set confirmed the CD74 prognostic significance and revealed that the absence of macrophage migration inhibitory factor (MIF) and inducible nitric oxide synthase (iNOS) was also associated with poor survival parameters. Consistent with the protein observation, tumor CD74 mRNA expression also correlated positively (P = 0.003) with OS in the melanoma TCGA data set. Conclusions: Our data validate CD74 as a useful prognostic tumor cell protein marker associated with favorable RFS and OS in stage III melanoma. Low or negative expression of MIF in both TMAs and of iNOS in the validation set also provided useful prognostic data. A disease-specific investigation of CD74's functional significance is warranted, and other markers appear intriguing to pursue. Clin Cancer Res; 22(12); 3016–24. ©2016 AACR.

22 September 2011 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KTKeiji Tanese
Keiji Tanese
EGElizabeth A. Grimm
Elizabeth A. Grimm
Suhendan EkmekciogluSuhendan Ekmekcioglu
Suhendan Ekmekcioglu
Melanoma appears to be heterogeneous in terms of its molecular biology, etiology and epidemiology. We previously reported that the expression of inducible nitric‐oxide synthase (iNOS) in melanoma tumor cells is strongly correlated with poor patient survival. Therefore, we hypothesized that nitric oxide (NO) produced by iNOS promotes the melanoma inflammatory tumor microenvironment associated with poor outcome. To understand the role of NO and iNOS in the melanoma inflammatory tumor microenvironment, polymerase chain reaction arrays of inflammatory and autoimmunity genes were performed on a series of stage III melanoma lymph node metastasis samples to compare the gene expression profiles of iNOS‐expressing and nonexpressing tumor samples. The results indicate that expression of CXC chemokine ligand 10 (CXCL10) was inversely correlated with iNOS expression, and the high CXCL10‐expressing cases had more favorable prognoses than the low CXCL10‐expressing cases. Functional studies revealed that treating iNOS‐negative/CXCL10‐positive melanoma cell lines with a NO donor suppressed the expression of CXCL10. Furthermore, scavenging NO from iNOS‐expressing cell lines significantly affected the chemokine expression profile. Culture supernatants from NO scavenger‐treated melanoma cells promoted the migration of plasmacytoid dendritic cells, which was diminished when the cells were treated with a CXCL10‐neutralizing antibody. CXCL10 has been reported to be an antitumorigenic chemokine. Our study suggests that the production of NO by iNOS inhibits the expression of CXCL10 in melanoma cells and leads to a protumorigenic tumor microenvironment. Inhibiting NO induces an antitumorigenic environment, and thus, iNOS should be considered to be an important therapeutic target in melanoma.